<!DOCTYPE html>
<html>
<head>
  <title>Genoomi terviklikkuse säilitamine ja vähiteke</title>
  <meta charset="utf-8">
  <meta name="description" content="Genoomi terviklikkuse säilitamine ja vähiteke">
  <meta name="author" content="Taavi Päll">
  <meta name="generator" content="slidify" />
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta http-equiv="X-UA-Compatible" content="chrome=1">
  <link rel="stylesheet" href="libraries/frameworks/io2012/css/default.css" media="all" >
  <link rel="stylesheet" href="libraries/frameworks/io2012/css/phone.css" 
    media="only screen and (max-device-width: 480px)" >
  <link rel="stylesheet" href="libraries/frameworks/io2012/css/slidify.css" >
  <link rel="stylesheet" href="libraries/highlighters/highlight.js/css/tomorrow.css" />
  <base target="_blank"> <!-- This amazingness opens all links in a new tab. -->  <link rel=stylesheet href="./assets/css/ribbons.css"></link>

  
  <!-- Grab CDN jQuery, fall back to local if offline -->
  <script src="http://ajax.aspnetcdn.com/ajax/jQuery/jquery-1.7.min.js"></script>
  <script>window.jQuery || document.write('<script src="libraries/widgets/quiz/js/jquery.js"><\/script>')</script> 
  <script data-main="libraries/frameworks/io2012/js/slides" 
    src="libraries/frameworks/io2012/js/require-1.0.8.min.js">
  </script>
  
  

</head>
<body style="opacity: 0">
  <slides class="layout-widescreen">
    
    <!-- LOGO SLIDE -->
        <slide class="title-slide segue nobackground">
  <hgroup class="auto-fadein">
    <h1>Genoomi terviklikkuse säilitamine ja vähiteke</h1>
    <h2>Onkobioloogia</h2>
    <p>Taavi Päll<br/>vanemteadur, VTAK</p>
  </hgroup>
  <article></article>  
</slide>
    

    <!-- SLIDES -->
    <slide class="" id="slide-1" style="background:;">
  <article data-timings="">
    <!-- Limit image width and height -->

<style type="text/css">
img {     
  max-height: 480px;     
  max-width: 600px; 
}
</style>

<style> .title-slide {
  background-color: #FFFFFF; /*#CBE7A5 #EDE0CF; ; #CA9F9D*/
}

.title-slide hgroup > h1{
 font-family: 'Oswald', 'Helvetica', sanserif; 
}

.title-slide hgroup > h1, 
.title-slide hgroup > h2 {
  color: #535E43 ;  /* ; #EF5150*/
}
</style>

<!-- Center image on slide -->

<script type="text/javascript" src="http://ajax.aspnetcdn.com/ajax/jQuery/jquery-1.7.min.js"></script>

<script type="text/javascript">
$(function() {     
  $("p:has(img)").addClass('centered'); 
});
</script>

<!-- Italic -->

<style>
em {
  font-style: italic
}
</style>

<!-- Bold -->

<style>
strong {
  font-weight: bold;
}
</style>

<style>
.title-slide {
background-image:url(http://www.nature.com/nrc/journal/v4/n4/images/nrc1321-f1.jpg);
background-repeat: no-repeat;
background-position: 0% 15%;
background-size: 100%;
background-color: #CBE7A5; /* ; ; */
}
</style>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="segue dark nobackground" id="slide-2" style="background:;">
  <hgroup>
    <h2>Recap</h2>
  </hgroup>
  <article data-timings="">
    
  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="segue dark nobackground" id="slide-3" style="background:;">
  <hgroup>
    <h2>Tüvirakud on mutageneesi märklauad</h2>
  </hgroup>
  <article data-timings="">
    
  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-4" style="background:;">
  <hgroup>
    <h2>Epiteelirakkude regeneratsioon sooleepiteelis</h2>
  </hgroup>
  <article data-timings="">
    <ul>
<li>Soole luumen sisaldab suures koguses toksiine ja baktereid.</li>
<li>Inimene kaotab umbes 10\(^{11}\) epiteelirakku (~200 g) igapäevaselt.</li>
<li>Laborihiire soole krüptis asuvad tüvirakud jagunevad elu jooksul umbes 1000 korda ilma jagunemispotentsiaali kaotamata ja kartsinogeensed mutatsioonid on harv nähtus.</li>
<li>Sooleepiteeli regeneerivad <strong>tüvirakud</strong> ja <strong>transitoorselt paljunevad rakud</strong> (<em>transit-amplifying, TA</em>).</li>
<li>Tüvirakud moodustavad 0.1-1% koe rakkudest.</li>
<li>Epiteelkoe rakud diferentseeruvad transitoorselt paljunevatest rakkudest.</li>
<li>Erütrotsüütide eluiga on ~120 päeva, mille järel nad põrnas endotsüteeritakse.</li>
<li>Käärsoole epiteeli eluiga on 5-7 päeva kui nad surevad.</li>
<li>Naha keratinotsüüdid surevad 20-30 päeva jooksul.</li>
</ul>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-5" style="background:;">
  <hgroup>
    <h2>Epiteeli struktuur minimeerib geenikahjustusi</h2>
  </hgroup>
  <article data-timings="">
    <h1>Tüvirakkude genoom on hästi kaitstud</h1>

<div style='float:left;width:48%;' class='centered'>
  <ul>
<li>Koes kõige seespool asub tüvirakunišš.</li>
<li>Krüpti põhjas asuvad 5 tüvirakku on soole sisu eest kaitstud tingituna oma asukohast ja lima poolt. </li>
<li>TA rakud jagunevad 2-3 korda ja diferentseeruvad.</li>
</ul>

</div>
<div style='float:right;width:48%;'>
  <p><img src="http://www.nature.com/nrm/journal/v15/n1/images_article/nrm3721-f1.jpg" style="width:460px")></p>

<p><footer class="source">Pilt: 
<a href="http://www.nature.com/nrm/journal/v15/n1/full/nrm3721.html">
Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration
</a>
</footer></p>

</div>
  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-6" style="background:;">
  <hgroup>
    <h2>Soole mukoosa kaitseb vähi eest</h2>
  </hgroup>
  <article data-timings="">
    <h1>GI vähi intsidents Muc2 hiirtel</h1>

<div style='float:left;width:48%;' class='centered'>
  <p><img src="http://www.gastrojournal.org/cms/attachment/2011260790/2033728947/gr5.jpg" style="width:350px"></p>

<p><footer class="source">Allikas: 
<a href="http://www.sciencemag.org/content/295/5560/1726.full">
Colorectal Cancer in Mice Genetically Deficient in the Mucin Muc2.
</a>
Pilt:
<a href="http://www.gastrojournal.org/article/S0016-5085(06)00762-1/fulltext">
Van der Sluis et al., 2006.
</a>
</footer></p>

</div>
<div style='float:right;width:48%;'>
  <table><thead>
<tr>
<th>Grupp (n)</th>
<th>Hiiri GI vähiga</th>
</tr>
</thead><tbody>
<tr>
<td>Muc2+/+</td>
<td></td>
</tr>
<tr>
<td>6 kuud (6)</td>
<td>0</td>
</tr>
<tr>
<td>1 aasta (18)</td>
<td>0</td>
</tr>
<tr>
<td>Muc2−/−</td>
<td></td>
</tr>
<tr>
<td>6 kuud (19)</td>
<td>3 (16%)</td>
</tr>
<tr>
<td>1 aasta (19)</td>
<td>13 (68%)</td>
</tr>
</tbody></table>

</div>
  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-7" style="background:;">
  <hgroup>
    <h2>Tüvirakud on mutageneesi märklauad</h2>
  </hgroup>
  <article data-timings="">
    <h1>Pikaealised rakud kontributeerivad vähi tekkesse</h1>

<ul>
<li>DMBA/TPA naha kartsinogeneesi mudeliga tekkinud papilloomid ja adenoomid pärinevad pigem vaikeolekus rakkudest (naha tüvirakud?) kui aktiivselt jagunevatest.

<ul>
<li>5-FU (<em>fluorouracil</em>) mis inhibeerib aktiivselt jagunevaid rakke ei vähendanud oluliselt papilloomide teket, <a href="http://cancerres.aacrjournals.org/content/57/16/3436.full.pdf">Morris et al., 1997</a>.</li>
</ul></li>
<li>CML-i põhjustav <strong><em>Philadelphia</em> kromosoom</strong> (Ph\(^1\), BRC-ABL translokatsioon) on olemas kõigis lümfoid ja müeloid raja rakkudes. 

<ul>
<li>See viitab, et mutatsioon on tekkinud <strong>pluripotentses</strong> tüvirakus.</li>
</ul></li>
</ul>

<p><img src="http://www.cell.com/cms/attachment/593400/4586019/gr1.jpg" style="width:300px" ></p>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-8" style="background:;">
  <hgroup>
    <h2>Tüvirakkude strateegiad</h2>
  </hgroup>
  <article data-timings="">
    <h1>Sümmeetriline ja asümmeetriline jagunemine</h1>

<p><img src="http://www.nature.com/nature/journal/v441/n7097/images/nature04956-f1.2.jpg" alt="sc"></p>

<p><footer class="source">Allikas: 
<a href="http://www.nature.com/nature/journal/v441/n7097/full/nature04956.html">
Asymmetric and symmetric stem-cell divisions in development and cancer.
</a>
</footer></p>

  </article>
  <!-- Presenter Notes -->
  <aside class="note" id="">
    <section>
      <ul>
<li>Asymmetric cell division: each stem cell generates one daughter stem cell and one daughter destined to differentiate. </li>
<li><strong>Population strategies</strong>. A population strategy provides dynamic control over the balance between stem cells and differentiated cells — a capacity that is necessary for repair after injury or disease. In this scheme, stem cells are defined by their &#39;potential&#39; to generate both stem cells and differentiated daughters, rather than their actual production of a stem cell and a differentiated cell at each division. </li>
<li>c, Symmetric cell division: each stem cell can divide symmetrically to generate either two daughter stem cells or two differentiated cells. </li>
<li>d, Combination of cell divisions: each stem cell can divide either symmetrically or asymmetrically.</li>
</ul>

    </section>
  </aside>
</slide>

<slide class="" id="slide-9" style="background:;">
  <hgroup>
    <h2>DNA kahjustuste vältimise strateegiad tüvirakkudes</h2>
  </hgroup>
  <article data-timings="">
    <p>Lisaks tüvirakkude suhteliselt <strong>aeglasemale jagunemisele</strong> ja nende <strong>asumisele anatoomiliselt kaitstud kohtades</strong>, toimib veel mitu teist mehhanismi:</p>

<ul>
<li><strong>Apoptoos</strong>, röntgenkiirguse poolt kahjustatud hiire soole krüpti tüvirakud lähevad kiirelt apoptoosi selle asemel et DNA kahjustusi parandada.</li>
<li><strong>Toksiinide aktiivne transport</strong> rakust välja: MDR1 (<em>multi drug resistance 1</em>).</li>
<li><strong>Asümmeetriline replitseerunud DNA jaotumine</strong>.</li>
</ul>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-10" style="background:;">
  <hgroup>
    <h2><em>Multi drug resistance</em> perekonna valgud</h2>
  </hgroup>
  <article data-timings="">
    <h1>Raku toksiinipumbad</h1>

<div style='float:left;width:48%;' class='centered'>
  <ul>
<li><strong>MRP</strong> (<em>MDR associated protein</em>) geeni transfektsioon SW-1573 inimese kopsu kartsinoomi rakkudesse muutis need rakud ravimiresistentseks.</li>
<li><strong>ABC transporterid</strong> on raku plasmamembraani ATP sõltuvad transpordivalgud, mis liigutavad rakust välja väga erinevaid substraate sh. toksiine.</li>
</ul>

</div>
<div style='float:right;width:48%;'>
  <table><thead>
<tr>
<th>Drug</th>
<th>Relative resistance</th>
</tr>
</thead><tbody>
<tr>
<td>Doxorubicin</td>
<td>2.7 ± 0.4</td>
</tr>
<tr>
<td>Daunorubicin</td>
<td>3.2 ± 0.8</td>
</tr>
<tr>
<td>Vincristine</td>
<td>5.3 ± 1.3</td>
</tr>
<tr>
<td>VP-16</td>
<td>4.9 ± 1.1</td>
</tr>
<tr>
<td>Colchicine</td>
<td>3.6 ± 0.1</td>
</tr>
<tr>
<td>Rhodamine</td>
<td>123 4.1 ± 0.3</td>
</tr>
<tr>
<td>Taxol</td>
<td>1.0 ± 0.1</td>
</tr>
</tbody></table>

<p><footer class="source">Allikas:
<a href="http://www.pnas.org/content/91/19/8822.full.pdf">
Zaman et al., 1994. 
</a>
</footer></p>

</div>
  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-11" style="background:;">
  <hgroup>
    <h2>P-glükovalgu struktuur</h2>
  </hgroup>
  <article data-timings="">
    <h1><em>P-glycoprotein/MDR1</em></h1>

<p><img src="http://www.rcsb.org/pdb/education_discussion/molecule_of_the_month/images/3g61_composite.jpg" style="width:400px"></p>

<p><footer class="source">Pilt: 
<a href="http://www.rcsb.org/pdb/101/motm.do?momID=123">
P-glycoprotein. 
</a> Wikipedia: 
<a href="http://en.wikipedia.org/wiki/P-glycoprotein">
P-gp wiki.
</a>
</footer></p>

  </article>
  <!-- Presenter Notes -->
  <aside class="note" id="">
    <section>
      <h2>P-glycoprotein</h2>

<p style="font-size:small" >
March 2010 Molecule of the Month by David Goodsell.

doi: 10.2210/rcsb_pdb/mom_2010_3.

Keywords: multidrug resistance, cancer chemotherapy, P-glycoprotein, membrane transport.
</p>

<h1>Introduction</h1>

<p style="font-size:small" >
Our environment is filled with toxic substances that attack our molecular machinery. Our cells protect themselves from these dangers in many ways. In some cases, they use enzymes to convert them into harmless compounds. In other cases, they sequester them safely out of the way. For others, cells build specialized pumps that find toxins and eject them outside, for safe disposal.
</p>

<h1>Clean Sweep</h1>

<p style="font-size:small" >
P-glycoprotein is the most common molecular pump protecting our cells from toxic molecules. It sits in the cell membrane and searches for foreign hydrophobic molecules. When it finds one, it grabs the molecule in a pocket deep within the protein, and then flips to a new conformation. The new conformation has an opening towards the outside of the cell, and the molecule is ejected. The whole process is powered by ATP to ensure that everything happens in a timely manner.
</p>

<h1>Powerful Pump</h1>

<p style="font-size:small" >
Of course, to be effective in its job, P-glycoprotein needs to be able to eject many different types of molecules. Scientists have found the P-glycoprotein pumps hundreds of different molecules, ranging is size from tens to hundreds of atoms. Most are hydrophobic and are normally found in the membrane. These include many toxic molecules, but also important drugs like cyclosporin and anticancer drugs. Thus, the action of P-glycoprotein can be both beneficial and harmful, protecting us from toxins but also reducing the effectiveness of the therapeutic drugs we take.
</p>

<h1>Blocking the Pump</h1>

<p style="font-size:small" >
Cancer cells in metastatic cancers are often particularly difficult to treat because they have become resistant to many different anticancer drugs. In some cases, these cells gain their multidrug resistance by building extra P-glycoprotein, which continually ejects the anticancer drugs out of the cancer cells. Therapeutic antibodies bind to small regions on P-glycoprotein and block the motions needed for pumping. Another approach is to find drugs that lodge in the active site of the protein, blocking its action from the inside.
</p>

    </section>
  </aside>
</slide>

<slide class="" id="slide-12" style="background:;">
  <hgroup>
    <h2>Asümmeetriline DNA jaotumine tütarrakkude vahel</h2>
  </hgroup>
  <article data-timings="">
    <h1>Raku jagunemisel peegeldub tütarrakkude saatus ka nende DNA-s.</h1>

<div style='float:left;width:48%;' class='centered'>
  <p><img src="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852587/bin/pbio.0050125.g001.jpg" alt=""></p>

</div>
<div style='float:right;width:48%;'>
  <ul>
<li>Kui tüvirakud jagunevad, siis õdekromatiidid mis sisaldavad vanemat DNA ahelat (pildil roheliselt fluorestseeruv) segregeeruvad ühte tütarrakku.</li>
<li>Vanem DNA segregeerub tavaliselt vähem diferentseerunud tütarrakku.</li>
</ul>

<p><footer class="source">Allikas: 
<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852587/">
Richard Robinson, 2007.
</a>
</footer></p>

</div>
  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-13" style="background:;">
  <hgroup>
    <h2>Matriits DNA selektiivne segregatsioon</h2>
  </hgroup>
  <article data-timings="">
    <h1>Konserveerunud DNA ahel jääb tüviraku kompartementi</h1>

<div style='float:left;width:48%;' class='centered'>
  <ul>
<li>DNA ahelad mida replikatsiooni käigus ei sünteesitud on nn. &quot;konserveerunud&quot; matriits ahelad.</li>
<li>Värskelt sünteesitud DNA on &quot;mitte-konserveerunud&quot;.</li>
<li><a href="http://www.nature.com/nature/journal/v255/n5505/abs/255197a0.html">Cairnsi hüpotees, 1975</a>: replitseerunud tüviraku matriits DNA segregeerub tüvirakust tütarrakule ja uuesti sünteesitud ahelat sisaldav DNA pärandub transitoorselt prolifereeruvale tütarrakule.</li>
</ul>

</div>
<div style='float:right;width:48%;'>
  <p><img src="http://jcs.biologists.org/content/115/11/2381/F1.large.jpg" alt=""></p>

</div>
  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-14" style="background:;">
  <hgroup>
    <h2>Tüviraku nišš ei jagune intensiivselt</h2>
  </hgroup>
  <article data-timings="">
    <h1>Somaatilised tüvirakud ei märgistu hästi DNA-sse lülituvate ühenditega, välja arvatud tekkimisel ja koe kahjustuste korral.</h1>

<ul>
<li>Somaatilised tüvirakud säilitavad oma tekkimisel DNA-sse lülitatud märgise (3H-tümidiin) väga pika-aegselt.</li>
<li>Lühiajaline kudede inkubeerimine 3H-tümidiiniga märgistab ainult transitoorselt jagunevad rakud ning koe uuenedes märgis kaob ruttu.</li>
<li>Hiirtel puberteedis rinnanäärme tüvirakkude nišši moodustumisel sisse viidud 3H-tümidiin jääb aga sinna pidama sest tüvirakud jagunevad veel sümmeetriliselt (tekib kaks tüvirakku).</li>
</ul>

<p><img src="assets/img/LRCmod.jpg.png" alt="lrcmod"></p>

<p><footer class="source">Pilt: 
<a href="http://dev.biologists.org/content/132/4/681.long">
Smith, 2005.
</a>
</footer></p>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-15" style="background:;">
  <hgroup>
    <h2>Konserveerunud DNA-d sisaldavad rakud karvanääpsus</h2>
  </hgroup>
  <article data-timings="">
    <p><em><strong>Label-retaining cells</strong></em> eksperimentaalselt defineeritud rakupopulatsioon,  mis säilitavad DNA-sse lülitatud märgise (nt. BrdU) ja mis peaksid olema aeglaselt jagunevad tüvirakud.</p>

<p><img src="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3050564/bin/nihms264176f2.jpg" style="width:300px"></p>

<p><footer class="source">Pilt: 
<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3050564/">
Hsu et al., 2011.
</a>
</footer></p>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-16" style="background:;">
  <hgroup>
    <h2>Mutantsete tüvirakkude teke läbi tsütotoksilisuse</h2>
  </hgroup>
  <article data-timings="">
    <h1>Krooniline koekahjustumine võib istutada mutantse DNA tüviraku nišši</h1>

<ul>
<li>Kartsinogeenid võivad toimida läbi koekahjustuse, kui kahjustada saavad ka tüvirakud.</li>
<li>Tüviraku sümmeetriline jagunemine võib põhjustada viimases S-faasis sünteesitud mutantse DNA jäämise tüviraku nišši.</li>
<li>Selline mutantne DNA omandab siis nn &quot;surematu&quot; staatuse.</li>
<li>Alkohol, mis toimib tuumori promootorina, põhjustab just sellist tüüpi kahjustusi suuõõne epiteelile.</li>
<li>Hüpoteetiline? <strong>super kartsinogeen</strong> oleks sellisel juhul aine mis on üheaegselt tsütotoksiline ja mutageenne.</li>
</ul>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-17" style="background:;">
  <hgroup>
    <h2>Biokeemilised DNA reparatsioonimehhanismid</h2>
  </hgroup>
  <article data-timings="">
    <p>Lisaks raku ja koe tasemel toimivatele mehhanismidele, mis peaksid minimeerima muteerunud somaatilise DNA säilimise ja pärandumise ekisteerivad loomulikult ka biokeemilised DNA reparatsioonimehhanismid.</p>

<p>Biokeemilised reparatsioonimehhanismid toimivad muutustele nagu:</p>

<ul>
<li><strong>replikatsioonivead</strong> mis tekivad DNA sünteesil (vale nukleotiidi lülitamine ahelase),</li>
<li><strong>nukleotiidide spontaansed biokeemilised muutused</strong> (depurineerumine ja depürimidineerumine, deamineerumine),</li>
<li><strong>mutageensete ühendite poolt põhjustatud nukleotiidide muutused</strong> (kiirgus, alkülatsioon).</li>
</ul>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-18" style="background:;">
  <hgroup>
    <h2>DNA replikatsiooni vead</h2>
  </hgroup>
  <article data-timings="">
    <h1>Imetajate genoomis on 15 DNA polümeraasi. Mõned funktsioneerivad genoomi replikatsioonil, kuid enamus toimivad DNA kahjustuste parandamisel.</h1>

<ul>
<li>DNA replikatsiooni viivad läbi DNA Pol \(\alpha\), Pol \(\delta\) ja Pol \(\epsilon\).</li>
<li>DNA polümeraasid lülitavad vigase nukleotiidi DNA-sse sagedusega 1/100000 aluspaari kohta (\(10{-5}\)).</li>
<li>Inimese genoomi replitseerimisel teeb see diploidses rakus oleva \(6\times10^{9}\) aluspaari kohta  60000 mutatsiooni.</li>
<li>Kui DNA Pol (\(\alpha\), \(\delta\), \(\epsilon\)) lülitab vale nukleotiidi ahelasse, korrigeerib ta selle kohe oma 3′–5′ eksonukleaasse aktiivsuse abil.</li>
</ul>

  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-19" style="background:;">
  <hgroup>
    <h2>Endogeensed biokeemilised protsessid</h2>
  </hgroup>
  <article data-timings="">
    
  </article>
  <!-- Presenter Notes -->
</slide>

<slide class="" id="slide-20" style="background:;">
  <hgroup>
    <h2>Eksogeensed mutageenid</h2>
  </hgroup>
  <article data-timings="">
    
  </article>
  <!-- Presenter Notes -->
</slide>

    <slide class="backdrop"></slide>
  </slides>
  <div class="pagination pagination-small" id='io2012-ptoc' style="display:none;">
    <ul>
      <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=1 title=''>
         1
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=2 title='Recap'>
         2
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=3 title='Tüvirakud on mutageneesi märklauad'>
         3
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=4 title='Epiteelirakkude regeneratsioon sooleepiteelis'>
         4
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=5 title='Epiteeli struktuur minimeerib geenikahjustusi'>
         5
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=6 title='Soole mukoosa kaitseb vähi eest'>
         6
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=7 title='Tüvirakud on mutageneesi märklauad'>
         7
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=8 title='Tüvirakkude strateegiad'>
         8
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=9 title='DNA kahjustuste vältimise strateegiad tüvirakkudes'>
         9
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=10 title='<em>Multi drug resistance</em> perekonna valgud'>
         10
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=11 title='P-glükovalgu struktuur'>
         11
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=12 title='Asümmeetriline DNA jaotumine tütarrakkude vahel'>
         12
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=13 title='Matriits DNA selektiivne segregatsioon'>
         13
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=14 title='Tüviraku nišš ei jagune intensiivselt'>
         14
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=15 title='Konserveerunud DNA-d sisaldavad rakud karvanääpsus'>
         15
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=16 title='Mutantsete tüvirakkude teke läbi tsütotoksilisuse'>
         16
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=17 title='Biokeemilised DNA reparatsioonimehhanismid'>
         17
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=18 title='DNA replikatsiooni vead'>
         18
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=19 title='Endogeensed biokeemilised protsessid'>
         19
      </a>
    </li>
    <li>
      <a href="#" target="_self" rel='tooltip' 
        data-slide=20 title='Eksogeensed mutageenid'>
         20
      </a>
    </li>
  </ul>
  </div>  <!--[if IE]>
    <script 
      src="http://ajax.googleapis.com/ajax/libs/chrome-frame/1/CFInstall.min.js">  
    </script>
    <script>CFInstall.check({mode: 'overlay'});</script>
  <![endif]-->
</body>
  <!-- Load Javascripts for Widgets -->
  
  <!-- MathJax: Fall back to local if CDN offline but local image fonts are not supported (saves >100MB) -->
  <script type="text/x-mathjax-config">
    MathJax.Hub.Config({
      tex2jax: {
        inlineMath: [['$','$'], ['\\(','\\)']],
        processEscapes: true
      }
    });
  </script>
  <script type="text/javascript" src="http://cdn.mathjax.org/mathjax/2.0-latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
  <!-- <script src="https://c328740.ssl.cf1.rackcdn.com/mathjax/2.0-latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML">
  </script> -->
  <script>window.MathJax || document.write('<script type="text/x-mathjax-config">MathJax.Hub.Config({"HTML-CSS":{imageFont:null}});<\/script><script src="libraries/widgets/mathjax/MathJax.js?config=TeX-AMS-MML_HTMLorMML"><\/script>')
</script>
<!-- LOAD HIGHLIGHTER JS FILES -->
  <script src="libraries/highlighters/highlight.js/highlight.pack.js"></script>
  <script>hljs.initHighlightingOnLoad();</script>
  <!-- DONE LOADING HIGHLIGHTER JS FILES -->
   
  </html>